Variable | Total (N = 2316) | BCLC stage 0 (N = 66) | BCLC stage A (N = 865) | BCLC stage B (N = 575) | BCLC stage C (N = 810) | |
---|---|---|---|---|---|---|
Male | 1748 (75.5) | 46 (69.7) | 605 (69.6) | 437 (76.0) | 660 (81.5) | |
Age (years) | 63 (19–99) | 62 (23–85) | 63 (28–92) | 64 (30–91) | 61 (19–99) | |
Smoking | 949 (41.0) | 28 (42.4) | 316 (36.5) | 232 (40.3) | 373 (46.0) | |
Alcohol use | 868 (37.5) | 22 (33.3) | 283 (32.7) | 218 (37.9) | 345 (42.6) | |
HBV positive | 1658 (71.6) | 44 (66.7) | 599 (69.2) | 414 (72.0) | 601 (74.2) | |
HCV positive | 696 (30.1) | 14 (21.2) | 253 (29.2) | 172 (29.9) | 257 (31.7) | |
Cirrhosis | 1395 (60.2) | 43 (65.2) | 511 (59.1) | 334 (58.1) | 507 (62.6) | |
Child–Pugh class A | 877 (37.9) | 66 (100) | 277 (32.0) | 225 (39.1) | 309 (38.1) | |
Tumor size (cm) | 6.1 (1.0–27) | 1.7 (1.0–2.0) | 2.9 (1.0–5.0) | 7.5 (1.2–21) | 9.4 (1.2–27) | |
Tumor number | 2.1 (1–11) | 1 (1–1) | 1.5 (1–3) | 2.5 (1–11) | 2.7 (1–11) | |
Treatment, surgery | 538 (23.2) | 27 (40.9) | 289 (33.4) | 164 (28.5) | 58 (7.2) | |
Mortality | 1302 (56.2) | 37 (56.9) | 472 (54.6) | 313 (54.4) | 480 (59.3) | |
Median follow-up duration (months) | 20 (0–96) | 52 (8–96) | 32 (1–96) | 19 (0–84) | 12 (0–79) |